COGT Bezuclastinib NDA Accepted for AdvSM, PDUFA June 2027

The FDA accepted Cogent Biosciences’ NDA for bezuclastinib in advanced systemic mastocytosis (AdvSM) and set a PDUFA target action date of June 29, 2027, with no advisory committee planned and no review issues identified.

The filing is bezuclastinib’s third under FDA review, joining the non-advanced systemic mastocytosis (NonAdvSM) NDA (PDUFA December 30, 2026) and the GIST NDA (November 30, 2026). The selective KIT D816V inhibitor is the centerpiece of a three-indication franchise built on a single molecule.

The registrational APEX trial backs the filing. Bezuclastinib showed an 81% pure pathological response and a 65% overall response rate, with 12-month progression-free survival of 79% and 12-month overall survival of 87% (median PFS and OS not yet mature). More than 90% of systemic mastocytosis cases carry the KIT D816V mutation, giving bezuclastinib a genetically defined target in a rare, aggressive disease with few effective options. The data were most recently presented at the 2026 European Hematology Association Congress.

The open risk is durability. The 12-month PFS of 79% and OS of 87% look strong, but neither median has been reached, so how long the response holds is still unproven, and that is the difference between a franchise and a niche. Safety held up in APEX with no intracranial bleeding or cognitive effects, though intracranial hemorrhage and thrombocytopenia remain the hematologic risks to watch with a KIT inhibitor.

Systemic mastocytosis is a rare disease in which abnormal mast cells accumulate in the bone marrow, liver, and spleen. In the advanced form, median survival can be measured in a matter of a few years, and the disease is driven in most cases by the KIT D816V mutation. Bezuclastinib is designed to bind and block that mutated receptor directly, stopping the uncontrolled mast cell proliferation it drives.

Bezuclastinib would not be first to market. Blueprint Medicines’ Ayvakit (avapritinib) has been approved for AdvSM since June 2021, so Cogent’s pitch is selectivity: bezuclastinib is designed to potently inhibit KIT D816V and related exon 17 mutations while limiting the off-target activity that drives avapritinib’s side effects. Ayvakit carries central nervous system side effects tied to blood-brain-barrier penetration, which is the opening Cogent argues bezuclastinib can exploit.

The two earlier decisions are the near-term catalysts. GIST lands November 30 and non-advanced systemic mastocytosis December 30, both within about nine weeks, giving bezuclastinib three shots on goal across 2026 and 2027. An approval would also give bezuclastinib a foot in the door for the much larger indolent systemic mastocytosis population, where Ayvakit already has a label. Cogent has staffed a commercial and medical team ahead of the expected launches, signaling it plans to sell bezuclastinib directly rather than through a partner.

What to watch next: the GIST PDUFA on November 30, the first test of whether bezuclastinib clears the FDA in any indication. Cogent closed at $32.31.

Source: Cogent Biosciences bezuclastinib AdvSM NDA acceptance press release

What It Means for the Trade

The AdvSM acceptance with no advisory committee planned and no review issues identified is the cleanest possible filing posture, but it is also the third shot on goal, not the first — and that sequencing is the trade. GIST reads out November 30 and non-advanced systemic mastocytosis December 30, both within about nine weeks, before this June 29, 2027 date arrives. Cogent at $32.31 is effectively a triple-binary over the next nine months.

The commercial tell is organizational: Cogent staffed its own commercial and medical team rather than partnering, signaling management believes the franchise economics justify selling bezuclastinib directly and keeping the upside in-house.

Mechanism and Pipeline Context

Bezuclastinib is a selective inhibitor of KIT D816V, the activating mutation in the KIT receptor that drives uncontrolled mast cell proliferation in more than 90% of systemic mastocytosis cases. The mutated receptor sits at the top of the disease’s causal chain, so inhibiting it directly addresses the driver rather than the symptoms of mast cell mediator release. Advanced systemic mastocytosis — abnormal mast cells accumulating in bone marrow, liver, and spleen — carries a median survival measured in a few years, and the APEX results (81% pure pathological response, 65% ORR, 12-month PFS 79%, 12-month OS 87%) support a genetically defined therapy in a disease with few effective options.

The design pitch against Ayvakit (avapritinib, approved for AdvSM since June 2021) is selectivity: bezuclastinib potently hits KIT D816V and related exon 17 mutations while limiting the off-target activity responsible for avapritinib’s characteristic side effects, which are tied to blood-brain-barrier penetration. Cogent’s argument is that a cleaner KIT inhibitor captures patients who cannot tolerate the incumbent, rather than out-efficacing it head to head. The open durability question is real — median PFS and OS have not been reached — but the 12-month landmark numbers give the launch franchise credibility.

Risks and What Could Go Wrong

1. The GIST or NonAdvSM decision slips or fails first — the three filings share one molecule; a rejection in any indication drags the others’ implied odds.
2. Durability disappoints — if median PFS lands short once matured, the franchise-vs-niche question resolves the wrong way.
3. Hematologic safety — intracranial hemorrhage and thrombocytopenia are the acknowledged KIT-inhibitor risks; a signal in longer exposure would compress the label.
4. Incumbent entrenchment — Ayvakit has years of AdvSM prescribing experience and a head start in the larger indolent population; a tolerability-based switching pitch is an uphill launch.